Nick Paul Taylor

Avalere Health has moved Amar Urhekar a rung up the corporate ladder, promoting the executive to CEO after a little more than one year as chief operating officer.

The pharma industry's standing among the U.S. public has reached a new steady state after the rise and fall it underwent as the pandemic ebbed and flowed.

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer's disease, paying BioArctic $100 million upfront for global rights to two preclinical antibodies.

Launches from companies including Boehringer Ingelheim and Bristol Myers Squibb could drive sales of schizophrenia drugs up to $17 billion by 2031 despite generic erosion of incumbent products, according to GlobalData.

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront.

A phase 3 trial of Novo Nordisk's next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value of the Danish drugmaker.

Inspectors found 111 open tickets for software defects categorized as catastrophic or severe patient harm. Several safety complaints were also listed that BD didn’t report within the required timeframe.

Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a long-acting challenger to Novartis and Roche's Xolair.

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It's welcome good news for Vertex following last week's subpar clinical results for its non-opioid analgesic.